Wolfe Research Downgrades Spyre Therapeutics to Peer Perform
Spyre Therapeutics Inc SYRE
$98.33
โผ -3.12%
($-3.17)
🎢 High Beta
📅 Earnings This Week
Open
$100.58
Prev Close
$101.50
Day Range
$95.27 โ $100.58
52W Range
$14.51 โ $105.09
Market Cap
$8.54B
Beta
2.97
EPS (TTM)
$-2.50
๐ Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2016-04-07 |
| Shares Out. | 86,840,000 |
| Website | spyre.com/ โ |
| Phone | 16176515940.0 |
| Employees | 112 |
| Net Income | -$69.0M |
| Total Assets | $764.0M |
| Total Liabilities | $93.1M |
| Equity | $670.8M |
About Spyre Therapeutics Inc
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting ฮฑ4ฮฒ7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Spyre Therapeutics Inc is a publicly traded company under the ticker symbol SYRE on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
๐ Analyst Ratings
23 analysts (2026-07-01)